AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 281 min read$TLRY

Tilray Brands (TLRY) hits 96.4% EBITDA target, 92.8% PSU payout

Tilray Brands (TLRY) reported that its Global General Counsel exercised 160,304 performance-based restricted stock units (PSUs) into common shares. The Compensation Committee certified 96.4% achievement of the 2023 EBITDA target, leading to a 92.8% payout of the PSU awards. 84,962 shares were withheld to cover tax obligations at $4.88 per share.

Original reporting
stocktitan.net
Published Aug 28, 2026, 12:07 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 2:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TLRY
Neutral
high confidence
Mentioned
$TLRY
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TLRYNeutralLow
01

Why it matters

Routine insider transaction with modest dilution; no immediate price catalyst.

02

Market read

Low relevance; primarily of interest to insiders and compliance monitors.

03

What to watch

Tax withholding reduces net shares received; the conversion does not affect cash flow.

Relevance 4/10Novelty 4/10Timing: post‑exercise Aug 26 2026

Background

Tilray Brands filed a Form 4 detailing the exercise of performance‑based RSUs tied to 2023 EBITDA targets.

Company-level read

Ticker impact

$TLRYNeutralHigh confidence
Context

Form 4 shows Tilray Global General Counsel Mitchell Gendel exercised 160,304 performance‑based RSUs, converting them to common stock and withholding shares for tax on Aug 26 2026.

Expected impact

Minimal short‑term impact; market may view as routine insider activity.

Evidence & confidence

The filing is a primary source disclosure of a routine equity award vesting; size is small relative to market cap.

Market effects

Sector

None significant; reflects Tilray's internal compensation practices.

Regional

US cannabis sector unchanged.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The vesting could signal confidence in EBITDA performance, suggesting upside if targets are consistently met.

Key entities

  • person
    Mitchell Gendel

    Tilray Global General Counsel executing PSUs.

Read at source← All news

Related articles

AUG 24
$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

aol.com3 min
AUG 23
$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

yahoo.com3 min
AUG 21
$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

fool.com3 min
AUG 7
$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

simplywall.st7 min
JUL 30
$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

yahoo.com6 min